Carmen Fava
A5090108654- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Quinazolinone synthesis and applications
- Fungal Plant Pathogen Control
- Biochemical and Molecular Research
- Kruppel-like factors research
- PI3K/AKT/mTOR signaling in cancer
- Monoclonal and Polyclonal Antibodies Research
- Synthesis of Tetrazole Derivatives
- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- Hematopoietic Stem Cell Transplantation
- Mast cells and histamine
- Neutropenia and Cancer Infections
- Click Chemistry and Applications
- HIV/AIDS drug development and treatment
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer-related Molecular Pathways
University of Turin
2016-2025
A. O. Ordine Mauriziano di Torino
2017-2024
Ospedale San Luigi Gonzaga
2009-2021
Policlinico S.Orsola-Malpighi
2014
Institut Català d'Oncologia
2013
University of Milano-Bicocca
2011
Screen
2011
The University of Texas MD Anderson Cancer Center
2007-2010
5T Torino (Italy)
2009
Ospedale Infermi di Rimini
1997
Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance aimed to collect data from adult who required hospitalisation for COVID-19.This multicentre, retrospective, cohort study included (aged ≥18 years) diagnosis of WHO-defined malignancy admitted 66 hospitals between Feb 25 May 18, 2020, laboratory-confirmed symptomatic COVID-19. Data cutoff analysis was June 22, 2020. primary...
Imatinib slows development of chronic myeloid leukemia (CML). However, available information on morbidity and mortality is largely based sponsored trials, whereas independent long-term field studies are lacking. Consecutive CML patients who started imatinib treatment before 2005 were in complete cytogenetic remission (CCyR) after 2 years (±3 months) eligible for enrollment the multicenter Long-Term (Side) Effects (ILTE) study. Incidence first serious nonserious adverse events loss CCyR...
Chronic Myeloid Leukemia (CML) patients in sustained "deep molecular response" (DMR) may stop TKI treatment without disease recurrence; however, half of them lose response shortly after withdrawing. Well-defined eligibility criteria to predict a safe discontinuation up-front are still missing. Relapse is probably due residual quiescent resistant leukemic stem cells (LSCs) supposedly transcriptionally low/silent and not easily detectable by BCR-ABL1 qRT-PCR. Bone marrow Ph+CML CD34+/CD38-LSCs...
Abstract Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival CML patients has become very close to normal. The next, ambitious, step is bring as many possible into a condition treatment-free remission (TFR). Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA; Italian Group for Hematologic Diseases Adult) Working Party (WP) developed project aimed at...
The most frequent BCR‐ABL1 fusion transcripts in chronic myeloid leukemia (CML) are the e13a2 (b2a2) and e14a2 (b3a2) ones. In imatinib era few studies addressing prognostic significance of transcript type early phase CML have been published. Overall, these suggest that patients response to is faster deeper. To evaluate if (e13a2 compared e14a2) affect clinical outcome newly diagnosed adult patients, 559 enrolled 3 prospective (NCT00514488, NCT00510926, observational study CML/023) were...
It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients phase CML who discontinued TKI deep molecular response. Seventy-two percent were imatinib, and 28% second generation at the time discontinuation. Median duration last was 77 months [Interquartile Range (IQR) 54;111], median response 46 (IQR 31;74). Duration shorter than imatinib (P
Comorbidities may affect survival and choice of treatment among cancer patients. In fact, comorbidities have been identified as significant determinants response to therapy in older patients with acute myeloid leukemia, breast cancer, head neck lung cancer. The Charlson comorbidity index adult evaluation-27 are lists a weight assigned from 1 6 for the former 0 3 latter score, derived relative risk estimates proportional hazard regression model using clinical data.We retrospectively evaluated...
Abstract To assess the most important features and clinical impact of pleural effusions, which are a common toxicity during dasatinib treatment often impair its high efficacy, 172 unselected consecutive patients with chronic myelogenous leukaemia in phase treated 27 Italian centres, when aged >60 years for resistance/intolerance to imatinib, were examined. During treatment, 52/172 (30.2%) presented effusion, was grades 1–2 38 3–4 14 (8.1% entire cohort patients), according WHO scale;...
Introduction: In chronic myeloid leukemia (CML), about half of the patients achieving a deep and stable molecular response with tyrosine kinase inhibitors (TKIs) may discontinue TKI treatment without disease recurrence. As such, treatment-free remission (TFR) has become an ambitious goal treatment. Given evidence that deepness duration are necessary but not sufficient requisites for successful TFR, additional biological criteria needed to identify CML suitable efficacious discontinuation....
Background/Objectives: Treatment with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has revolutionized disease management and transformed CML from a life-threatening to condition for many patients. However, overcoming resistance, particularly related leukemic stem cells (LSC) that can persist even when the bulk of are eliminated, remains significant challenge. Methods: K562 KU812 cell lines were treated vitro TKI Imatinib (IM). Gene expression, protein analysis,...
Development and validation of simple, rapid, reliable high-performance liquid chromatography (HPLC)-UV method for quantification major tyrosine kinase inhibitors, imatinib, dasatinib, nilotinib, in human plasma is presented. Chromatographic separation the drugs achieved on an RP-C(18) column at flow rate 0.9 mL/min 35°C; eluate monitored 267 nm. Mean intra-day inter-day precision all compounds are 2.5 13.3%; mean accuracy 13.9%; extraction recovery ranges within 40.24 81.81%. Calibration...
There have been few reports of a response to dasatinib or nilotinib after failure two prior sequential tyrosine kinase inhibitors. We report the outcome 82 chronic phase patients who received as third-line alternative inhibitor therapy. Thirty-four failed respond and were started on therapy while 48 switched failure. Overall, we obtained cytogenetic in 32 major molecular 13 patients; disease progression occurred 12 patients. At last follow up, 70 (85.4%) alive with median overall survival 46...
CML is a hematopoietic stem-cell disorder emanating from breakpoint cluster region/Abelson murine leukemia 1 (BCR/ABL) translocation. Introduction of different TKIs revolutionized treatment outcome in patients, but LSCs seem insensitive to and are detectable newly diagnosed resistant patients who discontinued therapy. It has been reported that aberrantly express some CD markers such as CD26 can be used for the diagnosis targeting. In this study, we confirmed presence CD26+ patients. To...
COVID-19 infection causes respiratory pathology with severe interstitial pneumonia and extra-pulmonary complications; in particular, it may predispose to thromboembolic disease. The current guidelines recommend the use of thromboprophylaxis patients COVID-19, however, optimal heparin dosage treatment is not well-established. We conducted a multicentre, Italian, retrospective, observational study on admitted ordinary wards, describe clinical characteristic at admission, bleeding thrombotic...
TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, dose reduction is often used prevent AEs. However, data on its impact successful treatment-free remission (TFR) are quite scarce. We conducted a retrospective study the outcome of subjects who discontinued low-dose from 54 Italian hematology centers participating Campus network. Overall, 1.785 5.108 (35.0%) regularly followed patients were treated with...